Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$8.0B
27M shares
52-week range
$236.73 – $343.12
52% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NYSE
CS
Borrow rate
0.40%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.29B | $2.31B | $2.55B | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B |
| Cost of revenue | $1.07B | $1.05B | $1.11B | $1.28B | $1.23B | $1.24B | $1.19B | $1.24B |
| Gross profit | $1.22B | $1.26B | $1.44B | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B |
| Gross margin | 53.5% | 54.4% | 56.5% | 56.1% | 55.9% | 53.4% | 53.7% | 52.0% |
| R&D | $199.2M | $202.7M | $217.8M | $260.6M | $256.9M | $247.4M | $295.9M | $256.9M |
| Operating income | −$108.6M | $229.7M | $421.3M | $500.3M | $482.6M | $337.8M | $269.0M | $270.5M |
| EBITDA | $674.7M | $2.46B | $5.08B | $5.59B | −$4.49B | −$654.8M | −$2.14B | $1.25B |
| Net income | $361.0M | $1.76B | $3.81B | $4.25B | −$3.63B | −$637.3M | −$1.84B | $759.9M |
| Net margin | 15.8% | 76.1% | 149.8% | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
| EPS (diluted) | 11.94 | 58.27 | 126.20 | 140.83 | -121.79 | -21.82 | -65.36 | 27.87 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.6B | $9.04 | $8.81–$9.22 | 2 |
| 2027 | $2.7B | $9.96 | $9.71–$10.16 | 2 |
| 2028 | $2.8B | $11.15 | $10.86–$11.36 | 1 |
| 2029 | $2.8B | $12.17 | $11.85–$12.41 | 1 |
Forward consensus · source: Financial Modeling Prep
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
www.bio-rad.comNo one on the platform currently holds BIO.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 1,684 | $469.4K |
No one on the platform has traded BIO yet.
| $14.3B |
| — |
| GMEDGlobus Medical, Inc. | $77.98 | -7.10% | $10.5B | — |
| GRFSGrifols, S.A. | $7.07 | -3.48% | $6.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 3.3× sales vs its 4.3× historical median P/S.
Fair value ≈ $384.79 · price $291.93 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$BIO Share Price: $282.01 Contract Selected: Dec 18, 2026 $290 Calls Buy Zone: $23.20 – $28.67 Target Zone: $37.07 – $45.30 Potential Upside: 51% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$D $TE $BIO $REGN https://factsheets.com/todays-top-volume-stocks-may-18-2026-t1-energy-surges-nextera-buys-dominion-nvda-eyes-earnings/
View on StockTwits ↗Bio-Rad Laboratories, Inc. ( $BIO ) SpicyTrade - Daily Stock Analysis https://youtu.be/qAodwuw3aWI?si=DJytoGU4aTyYjkK3
View on StockTwits ↗$BIDU $BRC $RAMP $D $BIO PRE-MARKET MOVERS: Currently Higher After Earnings: - Baidu (BIDU) up 4.6% - Brady (BRC) up 7.6% Currently Also Higher: - LiveRamp (RAMP) up 27.2% after Publicis (PUBGY) entered into an agreement to acquire the company for a total enterprise value of $2.2B - Dominion (D) up 13.7% after NextEra Energy and the company announced that they have entered into a definitive agreement to combine in an all-stock transaction - Bio-Rad Laboratories (BIO) up 7.5% after The Wall Street Journal reported activist investor Elliot Investment Management has built a big stake in the company - Ford (F) up 6.0% after the company and EDF Group announced the signing of a five-year framework agreement under which EDF power solutions will have the ability to procure up to four gigawatt hours of DC Block battery energy storage systems annually, representing a total potential volume of up to 20 GWh over the term of the agreement - Macy's (M) and Delta Air Lines (DAL) up 3.4% and 2.5%, respectively, after Berkshire Hathaway disclosed new positions in the companies Currently Lower After Earnings: - Gossamer Bio (GOSS) down 14.7% - Pioneer Power (PPSI) down 8.3% - iQiyi (IQ) down 2.5% - Soluna Holdings (SLNH) down 3.2% Currently Also Lower: - Regeneron (REGN) down 12.2% after reporting its fianlimab trial did not meet the primary endpoint - NextEra Energy (NEE) down 2.4% after the company and Dominion (D) announced that they have entered into a definitive agreement to combine in an all-stock transaction
View on StockTwits ↗$BIO (+7.8% pre) Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad - WSJ https://ooc.bz/l/102663
View on StockTwits ↗Elliott bought into $BIO to boost its weak stock, betting on turnaround and its valuable Sartorius stake driving future growth. https://notreload.xyz/xy/elliott-takes-stake-in-bio-rad-pushes-for-turnaround/
View on StockTwits ↗$BIO Bullish Piercing Candlestick Pattern Formed at Downtrend. Wait for the confirmation from the next day's candle.
View on StockTwits ↗$BIO Great piece that accurately captures BIO's current position. So if you want to refresh your understanding of BIO or learn about BIO for the first time, this is essential reading. https://everyticker.com/quote/BIO/analysis/bio-rad-s-ddpcr-gambit-can-innovation-outrun-execution-headwinds-nyse-bio
View on StockTwits ↗$BIO someone still holding 200k worth of calls, til 2 days, anyone know whats about to happen?
View on StockTwits ↗$BIO Current Stock Price: $246.62 Contracts to trade: $250.0 BIO May 15 2026 Call Entry: $4.20 Exit: $6.16 ROI: 47% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$BIO Current Stock Price: $254.32 Contracts to trade: $250.0 BIO May 15 2026 Call Entry: $13.50 Exit: $20.70 ROI: 53% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$IMDX ~$3.8, ~$135M mcap, now a catalyst-driven reset setup rather than a broken biotech. Broadwood (~40%) keeps adding even above prior $5.75 raise levels — usually a strong signal of long-horizon conviction into Q3 2026 regulatory window. Core shift: transplant rejection monitoring moving from invasive biopsies → blood-based donor DNA testing. Science is largely validated, now it’s execution + adoption. Key edge is distribution: kit-based model embedded into existing Bio-Rad ($BIO) PCR infrastructure across hospitals, not centralized labs. <150 days to major catalyst. Approval odds ~70% on diagnostic pathway. If adoption hits → asymmetric rerating (3–10x potential). If not → it stays a delayed turnaround story. Follow me 👉@ChipDistribution7 for real-time updates and everything. Let’s make moves!
View on StockTwits ↗Bio-Rad Laboratories cut its 2026 revenue outlook and reported Q1 results that missed expectations, reflecting continued pressure on its core life sciences business. The company now sees full-year revenue ranging from a ~3% decline to 0.5% growth, versus its prior forecast of 0.5%–1.5% growth. Q1 net loss totaled $527.1 million, compared with net income of $64 million a year earlier, primarily driven by a fair-value adjustment related to its investment in Sartorius AG. Adjusted EPS came in at $1.89, below the $1.98 consensus estimate. The outlook revision and earnings miss add to investor concerns about near-term growth visibility. Shares have fallen 16.7% year-to-date, including Thursday’s drop. $BIO
View on StockTwits ↗$STIM $BRKR $BIO $AHCO $ENOV this is just a few examples of companies in the medical device industry that sold more of their shares than they currently have. Add up the percentage of institutional, insiders and shares shorted. All well over 💯 percent!! How will the short sellers buy back shares that don’t exist? I think short sellers are in trouble of losing big betting against this industry.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.